Targeting glutamine metabolism in PIK3CA mutant colorectal cancers

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• PIK3CA mutations are common drivers in colorectal cancer (CRC).
• PIK3CA-mutant CRCs exhibit a metabolic dependency on glutamine.
• Glutamate pyruvate transaminase 2 (GPT2) is upregulated in these cancers.

Purpose of the Study:

• To investigate the role of glutamine metabolism in PIK3CA-mutant CRCs.
• To evaluate the therapeutic potential of targeting GPT2 in PIK3CA-mutant CRCs.

Main Methods:

• Analysis of gene expression in colorectal cancer cell lines and patient samples.
• In vivo studies using xenograft models of PIK3CA-mutant and wild-type CRCs.
• Pharmacological inhibition of GPT2.

Main Results:

• PIK3CA-mutant CRCs show increased reliance on glutamine metabolism.
• Upregulation of GPT2 was confirmed in PIK3CA-mutant CRCs.
• GPT2 inhibition effectively suppressed the in vivo growth of PIK3CA-mutant CRCs, but not wild-type CRCs.

Conclusions:

• Targeting glutamine metabolism, specifically through GPT2 inhibition, is a promising therapeutic strategy for PIK3CA-mutant colorectal cancers.
• This approach offers a potential precision medicine strategy for a subset of CRC patients.